✦ LIBER ✦

Disseminated mucormycosis of an immunocompromised multiple myeloma patient: impact of biopsy of extramedullary tumours in refractory multiple myeloma

✍ Scribed by S. Gattenlöhner; C. Unzicker; S. Wörner; G. Stuhler; H. Einsele; H. K. Müller-Hermelink

Book ID: 105989241
Publisher: Springer
Year: 2008
Tongue: English
Weight: 317 KB
Volume: 88
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0594-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differential expression of HOXB7 gene in

Differential expression of HOXB7 gene in multiple myeloma and extramedullary multiple myeloma patients

✍ Estela M. Novak; Camila Linardi; Martin Metzger; Durvanei A. Maria; Ricardo R. G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Lenalidomide is effective for extramedul

Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma

✍ José M. Calvo-Villas; Adrián Alegre; Carmen Calle; Miguel T. Hernández; Ricarda 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Incidence of extramedullary disease in p

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

✍ Short, K Detweiler; Rajkumar, S V; Larson, D; Buadi, F; Hayman, S; Dispenzieri, 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 163 KB

Renal safety of ibandronate in patients

Renal safety of ibandronate in patients with relapsed and refractory multiple myeloma

✍ A. Glasmacher; F. Hoffmann; K. Orlopp; M. von Lilienfeld-Toal; C. Hahn 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

The role of histone deacetylase inhibito

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

✍ Hajek, Roman; Siegel, David; Orlowski, Robert Z.; Ludwig, Heinz; Palumbo, Antoni 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 292 KB